SCHEMBL6475400

SCHEMBL6475400

COc1ccc2[nH]c(SCc3ccccc3N)nc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2E1 P05181 11/20 0.57
CYP2C8 P10632 11/20 0.57
CYP2D6 P10635 11/20 0.57
CYP2C9 P11712 11/20 0.57
CYP2B6 P20813 11/20 0.57
CYP2C19 P33261 11/20 0.57
SMN1; SMN2 Q16637 3/20 0.56
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
MEN1 O00255 1/20 0.56
NFKB1 P19838 1/20 0.56
NFKB2 Q00653 1/20 0.56
KMT2A Q03164 1/20 0.56
RELA Q04206 1/20 0.56
LMNA P02545 2/20 0.56
TP53 P04637 2/20 0.56
HTT P42858 1/20 0.55
CYP3A4 P08684 10/20 0.54
CYP1A2 P05177 9/20 0.54
NOS3 P29474 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL6483222 0.87 CYP2E1 (0.54) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL6475837 0.86 CYP2E1 (0.57) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL15693614 0.86 SMN1; SMN2 (0.67) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL6485273 0.85 HTT (0.55) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
Hydrochloric Acid SCHEMBL6481780 0.85 SMN1; SMN2 (0.65) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL9287032 0.84 SMN1; SMN2 (0.60) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL6475988 0.84 HPGD (0.50) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL10711880 0.84 CYP2E1 (0.55) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
Hydrochloric Acid SCHEMBL10717223 0.83 CYP2E1 (0.54) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6
SCHEMBL4650009 0.83 CYP2E1 (0.81) CYP2E1CYP2C8CYP2D6CYP2C9CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906078-B2 Method of using (H+/K+) ATPase inhibitors as antiviral agents PHARMACIA CORPORATION (US) 2005-06-14 US disclosed
US-20010047038-A1 Method of using (H+/K+) ATPase inhibitors as antiviral agents MOORMAN ALAN E (US) 2001-11-29 US disclosed
EP-0204215-B1 2-[(1H-benzimidazol-2-ylsulfinyl)methyl]-benzenamines G.D. Searle & Co. (US) 1993-08-11 EP disclosed
EP-0204215-A1 2-[(1H-benzimidazol-2-ylsulfinyl)methyl]-benzenamines G.D. Searle & Co. (US) 1986-12-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010047038-A1 Method of using (H+/K+) ATPase inhibitors as antiviral agents ATP4A, ATP1A1, ATP1A4 CYP2E1 691/4885CYP2C8 976/4885CYP2D6 707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.